T
Thomas Mandel Clausen
Researcher at University of California, San Diego
Publications - 48
Citations - 2609
Thomas Mandel Clausen is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Chondroitin sulfate & Heparan sulfate. The author has an hindex of 18, co-authored 41 publications receiving 1636 citations. Previous affiliations of Thomas Mandel Clausen include University of California, Berkeley & University of Copenhagen.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
Thomas Mandel Clausen,Thomas Mandel Clausen,Thomas Mandel Clausen,Daniel R. Sandoval,Charlotte B Spliid,Charlotte B Spliid,Charlotte B Spliid,Jessica Pihl,Jessica Pihl,Jessica Pihl,Hailee R. Perrett,Chelsea D. Painter,Anoop Narayanan,Sydney A. Majowicz,Elizabeth M. Kwong,Rachael N. McVicar,Bryan E. Thacker,Charles A. Glass,Zhang Yang,Jonathan L. Torres,Gregory J. Golden,Phillip L. Bartels,Ryan N. Porell,Aaron F. Garretson,Logan K. Laubach,Jared Feldman,Xin Yin,Yuan Pu,Blake M. Hauser,Timothy M. Caradonna,Benjamin P. Kellman,Cameron Martino,Philip L.S.M. Gordts,Sumit K. Chanda,Aaron G. Schmidt,Aaron G. Schmidt,Kamil Godula,Sandra L Leibel,Joyce Jose,Kevin D. Corbett,Andrew B. Ward,Aaron F. Carlin,Jeffrey D. Esko +42 more
TL;DR: A model in which viral attachment and infection involves heparan sulfate-dependent enhancement of binding to ACE2 is suggested, in which Manipulation of hepara sulfate or inhibition of viral adhesion by exogenous heparin presents new therapeutic opportunities.
Posted ContentDOI
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
Thomas Mandel Clausen,Daniel R. Sandoval,Charlotte B Spliid,Jessica Pihl,Hailee R. Perrett,Chelsea D. Painter,Anoop Narayanan,Sydney A. Majowicz,E. M. Kwong,Rachael N. McVicar,Bryan E. Thacker,Charles A. Glass,Zhang Yang,Jonathan L. Torres,Gregory J. Golden,Phillip L. Bartels,Ryan N. Porell,Aaron F. Garretson,Logan K. Laubach,Jared Feldman,Xin Yin,Yuan Pu,Blake M. Hauser,Timothy M. Caradonna,Benjamin P. Kellman,Cameron Martino,Gordts, Plsm, Chanda, S. K.,Aaron G. Schmidt,Kamil Godula,Sandra L Leibel,Joyce Jose,Kevin D. Corbett,Andrew B. Ward,Aaron F. Carlin,Jeffrey D. Esko +34 more
TL;DR: It is shown that SARS-CoV-2 spike protein interacts with cell surface heparan sulfate and angiotensin converting enzyme 2 (ACE2) through its Receptor Binding Domain and may represent new therapeutic opportunities for exogenous heparin.
Journal ArticleDOI
Structural and Functional Insight into How the Plasmodium falciparum VAR2CSA Protein Mediates Binding to Chondroitin Sulfate A in Placental Malaria
Thomas Mandel Clausen,Stig Christoffersen,Madeleine Dahlbäck,Annette Eva Langkilde,Kamilla E. Jensen,Mafalda Resende,Mette Ø. Agerbæk,Daniel Andersen,Besim Berisha,Sisse B. Ditlev,Vera V. Pinto,Morten Nielsen,Thor G. Theander,Sine Larsen,Ali Salanti +14 more
TL;DR: A small VAR2CSA antigen is constructed that has the capacity to induce highly adhesion-blocking antibodies and is constructed based on these novel PfEMP1 structure-function studies.
Journal ArticleDOI
Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein
Ali Salanti,Thomas Mandel Clausen,Mette Ø. Agerbæk,Nader Al Nakouzi,Nader Al Nakouzi,Madeleine Dahlbäck,Htoo Zarni Oo,Htoo Zarni Oo,Sherry Lee,Tobias Gustavsson,Jamie R. Rich,Bradley John Hedberg,Yang Mao,Line Barington,Marina Ayres Pereira,Janine LoBello,Makoto Endo,Ladan Fazli,Jo Soden,Chris K. Wang,Adam F. Sander,Robert Dagil,Susan Thrane,Peter Johannes Holst,Le Meng,Francesco Favero,Glen J. Weiss,Glen J. Weiss,Morten Nielsen,Jim Freeth,Torsten O. Nielsen,Joseph Zaia,Nhan L. Tran,Jeff Trent,John Babcook,Thor G. Theander,Poul H. Sorensen,Mads Daugaard,Mads Daugaard +38 more
TL;DR: The data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.
Journal ArticleDOI
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.
Shuofeng Yuan,Shuofeng Yuan,Xin Yin,Xin Yin,Xiangzhi Meng,Jasper Fuk-Woo Chan,Zi-Wei Ye,Laura Riva,Laura Riva,Lars Pache,Chris Chun-Yiu Chan,Pok Man Lai,Chris Chung-Sing Chan,Vincent Kwok-Man Poon,Andrew Chak-Yiu Lee,Naoko Matsunaga,Yuan Pu,Chun-Kit Yuen,Jianli Cao,Ronghui Liang,Kaiming Tang,Li Sheng,Li Sheng,Yushen Du,Wan Xu,Chit-Ying Lau,Ko-Yung Sit,Wing-Kuk Au,Runming Wang,Yu-Yuan Zhang,Yan-Dong Tang,Thomas Mandel Clausen,Thomas Mandel Clausen,Jessica Pihl,Jessica Pihl,Juntaek Oh,Juntaek Oh,Kong-Hung Sze,Anna Jinxia Zhang,Hin Chu,Kin-Hang Kok,Dong Wang,Dong Wang,Xue-Hui Cai,Jeffrey D. Esko,Ivan Hung,Ronald A. Li,Honglin Chen,Hongzhe Sun,Dong-Yan Jin,Ren Sun,Ren Sun,Sumit K. Chanda,Kwok-Yung Yuen +53 more
TL;DR: In this paper, the authors show that clofazimine-an anti-leprosy drug with a favorable safety profile-possesses inhibitory activity against several coronaviruses, and can antagonize the replication of SARS-CoV-2 and MERS-coV in a range of in vitro systems.